

Psychocardiology in Oncology: Holistic Approaches to Mitigate Mental and Cardiac Health Risks in Cancer Patients

Abstract

A Holistic Approaches to Mitigate Mental and Cardiac Health Risks in Cancer Patients are discussed. Cardiovascular problems are notable adverse consequences of cancer therapies, encompassing chemotherapy, radiation, and immunotherapy. Psychocardiology emphasizes the importance of a multidisciplinary strategy that incorporates oncologists, cardiologists, psychologists, and other healthcare professionals. Psychocardiology examines the impact of psychological factors, including stress, anxiety, and depression—prevalent among oncology patients—on the exacerbation of cardiovascular risks. Investigations in psychocardiology are enhancing our comprehension of the molecular and behavioral pathways that connect mental, cardiac, and oncological health.

Keywords :Psychocardiology , Health Risks , Cancer Patients, cardiovascular well-being

1. INTRODUCTION:

Psychocardiology is a burgeoning interdisciplinary domain that investigates the relationship between psychological and cardiovascular well-being. It is especially pertinent in oncology because to the intricate bidirectional interactions among cancer, its therapies, and both mental and cardiovascular health[1]. Numerous cancer therapies, including chemotherapy, radiation, and targeted treatments, provide a risk of cardiotoxicity, which may result in diseases such as heart failure, arrhythmias, or ischemic heart disease. Psychocardiology examines the impact of psychological factors, including stress, anxiety, and depression—prevalent among oncology patients—on the exacerbation of cardiovascular risks[2]. Chronic psychological stress stimulates the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system, leading to heightened inflammation, endothelial dysfunction, and increased cardiovascular strain[3]. These

variables not only exacerbate cardiac outcomes but also adversely affect cancer prognosis by impacting tumor development and immunological responses[4]. Psychocardiology emphasizes the significance of treating the long-term health of cancer survivors. Survivors frequently encounter increased risks of cardiovascular disease and psychiatric issues, necessitating integrated care methods. Psychological therapies, including cognitive-behavioral therapy (CBT), mindfulness-based stress reduction (MBSR), and psychosocial support, have demonstrated efficacy in alleviating stress and enhancing quality of life[5]. These measures may also diminish cardiovascular risks by enhancing autonomic balance, decreasing inflammation, and fostering compliance with healthy lifestyle modifications[6]. In clinical oncology, psychocardiology emphasizes the importance of a multidisciplinary strategy that incorporates oncologists, cardiologists, psychologists, and other healthcare professionals. Cardio-oncology programs are progressively integrating mental health assessments and psychological support to detect high-risk individuals at an early stage. Patients with pre-existing cardiovascular disorders or those receiving high-risk cancer treatments can benefit from tailored therapy that target both mental and cardiac health. This integrative care strategy enhances patient outcomes by concurrently addressing various facets of health[7].

Investigations in psychocardiology are enhancing our comprehension of the molecular and behavioral pathways that connect mental, cardiac, and oncological health. It offers essential insights for formulating tailored therapies that alleviate disease burden and enhance survivorship care. With the increasing incidence of cancer-associated cardiovascular problems, psychocardiology provides a paradigm for tackling the distinct challenges at the convergence of psychological health, cardiovascular wellness, and oncology. This comprehensive viewpoint is essential for improving patient treatment and promoting long-term survivorship among the increasing number of cancer patients[8, 9].

The interplay of cancer, mental health, and cardiovascular health is intricate and multidimensional, with each aspect significantly impacting the others. Cancer and its therapies frequently induce considerable psychological distress in patients, resulting in mental health disorders such as anxiety, depression, and post-traumatic stress disorder (PTSD)[10, 11]. These psychological problems might, in turn, intensify cardiovascular risks via mechanisms such as chronic stress, systemic inflammation, and dysregulation of the hypothalamic-pituitary-adrenal

(HPA) axis. Stress-induced stimulation of the HPA axis and sympathetic nervous system elevates cortisol and catecholamine levels, leading to hypertension, endothelial dysfunction, and various cardiovascular complications[12].

Cancer medicines, including chemotherapy, radiation therapy, and targeted treatments, may exacerbate this association by causing cardiotoxic consequences. Potential effects encompass cardiac failure, arrhythmias, and ischemic heart disease. Individuals with pre-existing mental health disorders may be more susceptible, as compromised psychological well-being can hinder compliance with treatment protocols, lifestyle changes, and cardiac rehabilitation efforts. Sadness and anxiety are associated with detrimental behaviors, such as smoking, inadequate nutrition, and lack of physical activity, which further increase cardiovascular risk[13, 14].

A comprehensive, multidisciplinary strategy is essential in cancer treatment since it covers the interrelated physical, emotional, and psychosocial requirements of patients, thereby improving both outcomes and quality of life[15]. Cancer impacts both the physical and the psyche, requiring a collaborative approach that incorporates oncologists, surgeons, radiologists, nurses, psychologists, dietitians, and additional professionals. This method guarantees that patients have thorough care customized to their specific need[16]. A multidisciplinary team can more effectively manage the side effects of cancer treatments, including pain, exhaustion, and cardiotoxicity, by coordinating efforts among oncologists, palliative care specialists, and cardiologists[17]. Psychologically, tackling mental health issues such as anxiety, despair, and terror through counseling or therapy enhances emotional resilience and adherence to treatment. Moreover, the inclusion of nutritionists and physical therapists fosters healthy lifestyle modifications, hence improving rehabilitation and diminishing the likelihood of recurrence[18]. Holistic care encompasses the patient's family, providing support networks and tools to address the emotional burden of caregiving. It also emphasizes survivability, highlighting long-term monitoring and well-being. A multidisciplinary approach integrates varied expertise to comprehensively address the physical, emotional, and social dimensions of the patient's journey, resulting in more individualized, effective, and compassionate cancer care[19].

2. CANCER AND CARDIOVASCULAR RISK:

Cardiovascular problems are notable adverse consequences of cancer therapies, encompassing chemotherapy, radiation, and immunotherapy. These medicines, although helpful in combating cancer, might unintentionally harm the heart and vascular system, resulting in both acute and chronic cardiotoxicity. Comprehending and mitigating these hazards is crucial for enhancing overall patient outcomes[20]. Chemotherapy drugs, including anthracyclines (e.g., doxorubicin), are recognized for their cardiotoxic effects. These medications can induce dose-dependent injury to cardiac myocytes, resulting in left ventricular dysfunction and heart failure. Additional chemotherapeutic drugs, such as fluoropyrimidines and taxanes, may precipitate arrhythmias or ischemia. Recent targeted medicines, including HER2 inhibitors (e.g., trastuzumab), provide cardiovascular hazards, particularly when used in conjunction with conventional medications, hence increasing the likelihood of heart failure[21].

Radiation therapy, especially when aimed at the chest, can inflict harm on the heart and adjacent blood vessels. Prolonged consequences may encompass myocardial fibrosis, pericarditis, valve pathology, coronary artery disease, and conduction irregularities. These problems frequently emerge years post-treatment, highlighting the necessity for prolonged cardiovascular surveillance[22].

Immunotherapy, particularly immune checkpoint inhibitors, has transformed cancer treatment; yet, it is linked to immune-related adverse events (irAEs). Myocarditis, an uncommon although possibly lethal consequence, is a significant worry[23]. Concerns encompass pericarditis, arrhythmias, and vasculitis, stemming from increased immunological activation. Cardio-oncology has arisen as a specific discipline aimed at the prevention, early identification, and management of cardiovascular problems in cancer patients to tackle these challenges. Strategies encompass baseline cardiac evaluations, continuous monitoring throughout treatment, and the administration of cardioprotective medications such as beta-blockers or ACE inhibitors. Modifications in lifestyle, including dietary changes, physical activity, and cessation of smoking, are essential in mitigating cardiovascular risks[24].

2.1. CANCER-INDUCED INFLAMMATION AND ITS IMPACT ON THE HEART:

Inflammation generated by cancer markedly affects the heart, facilitating the onset and advancement of cardiovascular problems. Inflammation is a characteristic of cancer, propelled by tumor cells, immunological responses, and systemic alterations inside the body[25]. This persistent inflammatory condition not only facilitates tumor proliferation and metastasis but also engenders a pro-inflammatory milieu that might negatively impact the cardiovascular system. Cytokines include interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF- α), and C-reactive protein (CRP) are frequently raised in patients with cancer. These inflammatory mediators can impair endothelial function, enhance oxidative stress, and expedite atherosclerosis, hence elevating the risk of coronary artery disease. Chronic inflammation also facilitates myocardial remodeling and fibrosis, potentially resulting in heart failure with preserved ejection fraction (HFpEF)[26].

Cancer-induced inflammation modifies the coagulation cascade, resulting in a hypercoagulable condition. This elevates the likelihood of thromboembolic occurrences, including deep vein thrombosis, pulmonary embolism, and, in critical instances, ischemic strokes or myocardial infarctions[27]. The interplay of increased clotting risk and systemic inflammation imposes considerable stress on the cardiovascular system. In addition to direct cardiovascular consequences, cancer-related inflammation interacts with cancer therapies to exacerbate risks[28]. Systemic inflammation can exacerbate the cardiotoxicity of chemotherapy, radiotherapy, and immunotherapy by heightening vulnerability to cardiac injury and vascular damage.

Mitigating the cardiovascular consequences of cancer-related inflammation necessitates a comprehensive strategy. Anti-inflammatory treatments, including statins or colchicine, may reduce risks in some patients. Consistent cardiovascular surveillance, in conjunction with strategies to mitigate cancer-related inflammation via targeted medicines, is essential for minimizing cardiac consequences. By addressing this interaction, healthcare providers can enhance cardiovascular protection while ensuring efficient cancer treatment[29].

2.2. SHARED RISK FACTORS BETWEEN CANCER AND CARDIOVASCULAR DISEASES (E.G., SMOKING, OBESITY, AND STRESS):

Cancer and cardiovascular diseases (CVD) share several modifiable and non-modifiable risk factors, reflecting overlapping biological mechanisms and lifestyle influences. These shared risk factors highlight the interconnectedness of the two conditions and underscore the importance of a holistic approach to prevention and management[30].

Table 1 This table highlights the overlapping risk factors and mechanisms that underline the strong relationship between cancer and cardiovascular diseases, emphasizing the need for preventive and integrated care strategies[31-34].

Risk Factor	Cancer	Cardiovascular Disease	Shared Mechanism
Smoking	Increases risk of lung, throat, bladder, and other cancers	Major cause of coronary artery disease, stroke, and peripheral artery disease	Promotes oxidative stress, systemic inflammation, endothelial dysfunction, and DNA damage
Obesity	Associated with cancers such as breast, colorectal, and endometrial	Contributes to hypertension, atherosclerosis, and heart failure	Leads to chronic inflammation, insulin resistance, dyslipidemia, and hormonal imbalances
Stress	Linked to tumor progression and worsened cancer outcomes	Elevates risk of hypertension, arrhythmias, and heart disease	Activates the HPA axis and sympathetic nervous system, increasing cortisol levels and inflammation
Physical Inactivity	Increases risk of colon, breast, and other cancers	Linked to obesity, hypertension, and cardiovascular disease	Reduces metabolic efficiency, increases body fat, and exacerbates inflammation
Diet (Poor Nutrition)	High-fat, low-fiber diets increase cancer risk (e.g., colorectal cancer)	Contributes to dyslipidemia, hypertension, and diabetes	Promotes obesity, oxidative stress, and systemic inflammation
Alcohol Consumption	Linked to liver, breast, and	Raises blood pressure, increases risk of	Causes oxidative stress, disrupts lipid metabolism,

	esophageal cancers	arrhythmias and cardiomyopathy	and damages tissues
Chronic Inflammation	Promotes tumorigenesis and cancer progression	Drives atherosclerosis, heart failure, and vascular damage	Elevates pro-inflammatory cytokines, such as IL-6, TNF- α , and CRP
Diabetes	Associated with pancreatic, liver, and endometrial cancers	Increases risk of coronary artery disease and heart failure	Causes hyperglycemia, insulin resistance, and vascular inflammation
Aging	Key risk factor for most cancers	Strongly associated with cardiovascular diseases	Accumulates cellular damage, promotes oxidative stress, and reduces repair mechanisms
Genetic Factors	Certain mutations increase cancer susceptibility	Familial hypercholesterolemia and other genetic disorders elevate CVD risk	Shared genetic predispositions, such as mutations affecting inflammation and metabolism

3. MENTAL HEALTH CHALLENGES IN CANCER PATIENTS:

Cancer patients face a wide range of mental health challenges that profoundly impact their emotional well-being, quality of life, and treatment outcomes. The diagnosis of cancer often triggers intense psychological distress, including feelings of fear, uncertainty, and grief. Common mental health issues in cancer patients include anxiety, depression, post-traumatic stress disorder (PTSD), and adjustment disorders[35, 36]. **Anxiety** is prevalent in cancer patients, stemming from fears about prognosis, treatment side effects, and the potential for recurrence. This constant worry can disrupt sleep, concentration, and daily functioning. Similarly,

depression is common, affecting up to 25% of cancer patients. It may result from the emotional burden of the disease, physical symptoms like fatigue and pain, or treatment-related side effects. Untreated depression can hinder adherence to treatment and reduce overall survival rates[37, 38]. **Post-traumatic stress symptoms (PTSS)** may develop due to the traumatic nature of a cancer diagnosis and treatment experience. Intrusive thoughts, avoidance behaviors, and hypervigilance are hallmark symptoms that can persist even after successful treatment. Additionally, **adjustment disorders** are frequent as patients struggle to cope with the life-altering implications of their illness[39, 40].

These mental health challenges are exacerbated by social isolation, financial stress, body image concerns, and fears of mortality. Importantly, mental health issues can also worsen physical health outcomes, as chronic stress and emotional distress can lead to systemic inflammation, weakened immune responses, and cardiovascular strain[41, 42]. To address these challenges, a holistic approach is essential. Early screening for mental health concerns using validated tools, such as the Distress Thermometer or PHQ-9, enables timely identification and intervention. Evidence-based interventions like cognitive-behavioral therapy (CBT), mindfulness-based stress reduction (MBSR), and supportive psychotherapy can help patients manage distress and improve coping mechanisms. Pharmacological treatments, such as antidepressants or anxiolytics, may be appropriate for some patients[43-45].

Integrating mental health support into cancer care not only improves psychological well-being but also enhances treatment adherence, physical health outcomes, and overall quality of life. By recognizing the profound interplay between mental and physical health in cancer patients, healthcare providers can deliver more compassionate and effective care[46].

Table 2 This table outlines the various mental health challenges that cancer patients face, highlighting the profound effects on their overall well-being and cancer care[47, 48].

Mental Health Challenge	Description	Impact on Cancer Care	Common Symptoms
Anxiety	Persistent worry or fear related to diagnosis, treatment, or prognosis	May affect treatment adherence, exacerbate physical symptoms,	Restlessness, excessive worry, fatigue, difficulty concentrating

		and reduce quality of life	
Depression	Feelings of sadness, hopelessness, or loss of interest in activities	Can lead to poor self-care, decreased social support, and compromised immune function	Low mood, loss of interest, changes in appetite, sleep disturbances
Post-Traumatic Stress Disorder (PTSD)	Emotional distress from traumatic cancer experiences or treatment procedures	May impair treatment adherence, emotional processing, and coping strategies	Flashbacks, nightmares, hypervigilance, emotional numbness
Body Image Disturbances	Altered perception of self due to visible changes (e.g., hair loss, scars)	Can reduce self-esteem, increase isolation, and contribute to depression and anxiety	Feelings of unattractiveness, social withdrawal, dissatisfaction with appearance
Fatigue and Sleep Disorders	Persistent tiredness and sleep disturbances related to cancer and treatments	Can worsen physical health, impair cognitive function, and hinder emotional well-being	Excessive tiredness, insomnia, poor sleep quality
Fear of Recurrence	Ongoing worry about cancer returning after treatment	Increases anxiety and distress, may reduce quality of life and increase healthcare utilization	Constant fear of relapse, intrusive thoughts about cancer
Social Isolation	Withdrawal from social interactions due to illness, treatment side effects, or emotional distress	Can lead to depression, loneliness, and reduced access to supportive networks	Loneliness, lack of social engagement, reduced communication with others

Cognitive Impairment (Chemobrain)	Mental fog or cognitive dysfunction caused by chemotherapy or other treatments	Affects daily functioning, work, and social interactions, leading to frustration and stress	Forgetfulness, difficulty concentrating, mental fatigue
Adjusting to Life Changes	Difficulty accepting changes in lifestyle, relationships, or physical appearance	May lead to depression, frustration, or difficulty with coping strategies	Stress, anxiety about future, difficulty adapting to new circumstances

Addressing these challenges through psychological support, counseling, and therapies can greatly improve patients' quality of life and treatment outcomes.

4. THE PSYCHOCARDIOLOGY FRAMEWORK:

The psychocardiology framework is an interdisciplinary approach that amalgamates psychology and cardiology to tackle the psychological and circulatory health issues encountered by patients. This approach acknowledges the reciprocal relationship between mental health and cardiovascular disorders, highlighting the necessity for integrated care that addresses both psychological and cardiac health[49]. Psychological variables, including stress, anxiety, and depression, are recognized to affect cardiovascular health by inducing systemic inflammation, autonomic dysfunction, and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Mental health disorders can elevate the risk of cardiovascular diseases such as hypertension, coronary artery disease, and heart failure. Conversely, cardiovascular disorders can intensify psychological symptoms, establishing a feedback loop that deteriorates both physical and mental health[50, 51].

The psychocardiology framework seeks to address these relationships through a multidisciplinary approach that includes cardiologists, psychologists, psychiatrists, and other healthcare professionals. Timely recognition and treatment of psychological distress, together with cardiovascular surveillance and therapies, are essential for enhancing patient outcomes. Cognitive-behavioral therapy (CBT), stress management strategies, and social support are essential in mitigating cardiovascular risk and promoting recovery[52]. This comprehensive

model acknowledges the significance of addressing both mental and emotional well-being, enhancing patient quality of life, mitigating health risks, and fostering improved long-term health outcomes[53, 54].

The integration of psychological, oncological, and cardiological care is a comprehensive, patient-centered approach that aims to address the complex interplay between cancer, mental health, and cardiovascular health. This model acknowledges that cancer patients face not only physical challenges but also significant psychological and cardiovascular risks, especially due to the side effects of cancer treatments[55].

- **Psychological care** is essential for addressing mental health issues such as anxiety, depression, stress, and post-traumatic stress disorder (PTSD) that are common in cancer patients. These conditions can significantly impact treatment adherence, recovery, and overall well-being. Psychological interventions, including counseling, cognitive-behavioral therapy (CBT), mindfulness, and stress reduction techniques, are vital in managing emotional distress and improving patients' quality of life[56].
- **Oncological care** focuses on treating cancer through chemotherapy, radiation, surgery, and immunotherapy. However, these treatments often present side effects that strain cardiovascular health, such as cardiotoxicity from chemotherapy or radiation-induced heart damage. Oncologists must collaborate with cardiologists to monitor cardiovascular risks, adjust cancer treatments if necessary, and manage the effects of treatments on the heart[57].
- **Cardiological care** ensures the early detection and management of cardiovascular complications, such as heart failure, arrhythmias, and ischemic heart disease, that may arise from cancer treatments or pre-existing conditions. Cardio-oncology programs play a crucial role in providing specialized care to patients at risk[58].

By integrating psychological, oncological, and cardiological care into a multidisciplinary framework, healthcare providers can offer more holistic and personalized treatment plans, reducing the risks of complications and improving the overall well-being and long-term outcomes for cancer patients. This approach fosters collaboration among specialists, ensuring

that all aspects of a patient's health—physical, mental, and emotional—are addressed simultaneously.

5. HOLISTIC INTERVENTIONS:

Holistic interventions in healthcare emphasize treating the whole person—body, mind, and spirit—rather than focusing solely on a specific illness. For cancer patients, this approach includes integrating physical treatments with psychological, emotional, and social support. Common interventions include counseling, cognitive-behavioral therapy (CBT), mindfulness practices, stress management, and nutritional counseling. Exercise and physical therapy promote strength and well-being, while complementary therapies like acupuncture, massage, and yoga can alleviate side effects. This integrative approach fosters a sense of empowerment, reduces stress, enhances emotional resilience, and improves overall quality of life, supporting both recovery and long-term health[59].

Cancer is a life-altering diagnosis that not only affects the body but also severely impacts mental and cardiac health. The physical and emotional stress of cancer treatments, including chemotherapy and radiation, can create significant risks for patients, particularly concerning mental health and cardiovascular function. Holistic approaches offer a well-rounded method to help cancer patients manage these risks through complementary therapies that focus on the body, mind, and spirit. These interventions aim to reduce anxiety, depression, and stress, while also improving heart health, fostering emotional resilience, and supporting overall well-being[60].

5.1. Mental Health Challenges in Cancer Patients

The psychological impact of cancer is profound, with a high incidence of depression, anxiety, and post-traumatic stress disorder (PTSD) among patients. Studies have shown that up to 40% of cancer patients experience depression at some point during their treatment. Stress, pain, and uncertainty about the future exacerbate these mental health issues. Additionally, the side effects of treatments can affect cognitive function and emotional regulation, making it crucial to adopt strategies that provide emotional support[61].

5.2. Cardiac Health Risks in Cancer Patients

Cancer therapies such as chemotherapy and radiation can strain the cardiovascular system. Certain chemotherapy drugs, like anthracyclines, are known to cause cardiotoxicity, which can lead to long-term heart damage. Cancer patients also face an elevated risk of developing hypertension and arrhythmias due to the physical stress imposed by the disease and its treatment. These cardiac health risks necessitate early identification and proactive management[62].

5.3. Holistic Approaches to Mitigate Health Risks[63-67]:

1. Mind-Body Practices

- **Yoga:** Yoga is a powerful practice that integrates physical postures, breathing exercises, and meditation to reduce stress, anxiety, and depression. It has been shown to enhance heart rate variability, lower blood pressure, and improve mood.
- **Mindfulness Meditation:** Mindfulness techniques can reduce rumination and stress, promoting relaxation and emotional regulation. Regular mindfulness practice has been found to reduce cortisol levels, decrease anxiety, and improve overall quality of life in cancer patients.

2. Nutritional Support

- **Anti-inflammatory Diets:** A diet rich in antioxidants, omega-3 fatty acids, and plant-based foods can reduce inflammation, which plays a significant role in both mental health and cardiovascular risk. Nutrient-dense foods also support overall healing and immune function during cancer treatment.
- **Supplements:** Omega-3 fatty acids, vitamin D, and magnesium have been found to support both mental and heart health, offering anti-inflammatory benefits and supporting cognitive function.

3. Physical Activity

- **Aerobic Exercise:** Exercise is a well-established way to improve cardiovascular function and mitigate treatment-induced cardiovascular risks. Studies suggest that moderate-intensity aerobic activity can help reduce fatigue, improve heart health, and reduce symptoms of depression.
- **Strength Training:** Light strength training can improve muscle mass and strength, reducing the likelihood of treatment-related muscle atrophy. It can also support heart health by improving circulation and blood pressure regulation.

4. Complementary Therapies

- **Acupuncture:** Acupuncture has shown promise in reducing chemotherapy-induced nausea, stress, and fatigue. It may also have benefits for mental health, improving mood and sleep.
- **Massage Therapy:** Therapeutic massage can help alleviate pain, reduce anxiety, and improve blood circulation, which supports both mental well-being and cardiovascular health.

Table 3 Holistic Approaches to Mitigate Mental and Cardiac Health Risks in Cancer Patients[68-71]

Approach	Mental Health Benefits	Cardiac Health Benefits	Notes
Yoga	Reduces anxiety and depression, enhances mood	Improves heart rate variability, reduces BP	Improves overall well-being and physical flexibility
Mindfulness Meditation	Decreases anxiety, stress, and rumination	Lowers cortisol, reduces hypertension	Promotes emotional regulation and relaxation
Anti-inflammatory Diet	Supports cognitive function, reduces depression	Reduces inflammation, supports heart health	Rich in omega-3s, antioxidants, and plant-based foods
Omega-3 Supplements	Enhances mood regulation, reduces depressive symptoms	Reduces inflammation, lowers triglycerides	Supports brain and heart health during treatment

Aerobic Exercise	Reduces stress, depression, and fatigue	Improves cardiovascular endurance and BP	Beneficial for reducing treatment-related fatigue
Acupuncture	Reduces anxiety, improves sleep	Improves circulation, reduces blood pressure	Effective for stress relief and pain management

6. TECHNOLOGY AND AI IN PSYCHOCARDIOLOGY:

Psychocardiology is a nascent interdisciplinary domain that examines the relationship between psychological wellness and cardiovascular health. It acknowledges the significant impact that psychological issues, including stress, anxiety, sadness, and trauma, can exert on cardiovascular health, and conversely. Technological and artificial intelligence advancements are crucial in transforming psychocardiology through enhanced early identification, individualized treatment strategies, and ongoing monitoring of mental and heart health. These innovations facilitate the integration of psychological and cardiovascular care, providing patients with more complete and efficient therapies[72, 73].

The Function of Technology in Psychocardiology

Technological advancements in psychocardiology have greatly enhanced our comprehension of the relationship between mental health and cardiovascular health. A significant innovation is the utilization of wearable gadgets and mobile health applications that measure heart rate, blood pressure, and stress levels in real-time. These instruments enable patients and healthcare professionals to continuously monitor cardiovascular and psychological metrics, yielding critical data for informed decision-making. Devices like smartwatches and fitness trackers can identify abnormal heart rhythms, increased blood pressure, or indications of worry, enabling patients to address their problems proactively[74]. Biofeedback technology has become a prevalent instrument in psychocardiology. Biofeedback employs sensors to assess physiological functions, including heart rate, respiration, and skin temperature, delivering instantaneous feedback to the patient. By mastering the regulation of these physiological responses, patients can mitigate stress and anxiety, resulting in enhanced cardiovascular health. This method has demonstrated therapeutic advantages for ailments such as hypertension, arrhythmias, and cardiovascular disease[75].

6.1. ARTIFICIAL INTELLIGENCE IN PSYCHOCARDIOLOGY:

Artificial intelligence is revolutionizing psychocardiology by facilitating more precise diagnosis, forecasting health consequences, and customizing treatment regimens. AI systems can evaluate extensive data from wearable devices, electronic health records, and psychological tests to discern patterns and connections that may elude human clinicians. This data-driven methodology enables doctors to more precisely identify at-risk individuals at an earlier stage, facilitating faster intervention and improved treatment of mental and cardiovascular health[76]. AI algorithms can aid in formulating tailored treatment regimens by examining the distinct psychological and physiological traits of each patient. AI can forecast a patient's response to certain interventions, such as pharmacological treatments or behavioral therapies, in cases of chronic stress. This individualized technique guarantees that therapies are more efficacious and customized to the patient's exact requirements, enhancing both psychological and cardiac results[77]. Machine learning methodologies are employed to forecast the likelihood of cardiovascular incidents in individuals with psychological illnesses. Research indicates that AI algorithms may assess variables such as heart rate variability, cortisol concentrations, and self-reported stress to forecast the probability of a heart attack or stroke in individuals exhibiting elevated anxiety or depression levels. This enables healthcare personnel to intervene promptly, potentially averting life-threatening cardiovascular incidents[78].

In therapeutic environments, artificial intelligence and technology are progressively used into psychocardiology techniques. AI-driven virtual mental health consultations facilitate remote psychological assistance, enhancing accessibility to mental health services for those with cardiovascular diseases. Virtual cognitive behavioral therapy (CBT) platforms can assist patients in managing stress and anxiety, thereby complementing conventional cardiac care[79]. AI-driven decision support systems are aiding cardiologists and psychologists in providing enhanced, more cohesive care. AI systems can identify individuals exhibiting both heart disease and psychiatric symptoms, urging practitioners to consider both facets of the patient's health. These tools promote a comprehensive approach to patient care by optimizing the treatment process and improving collaboration between mental health specialists and cardiologists[80]. Notwithstanding the potential of technology and AI in psychocardiology, some problems persist. Concerns regarding data privacy and security are paramount, especially in relation to sensitive health information. Moreover, further investigation is required to comprehensively elucidate the intricate relationship between psychological aspects and cardiovascular health, guaranteeing that

AI algorithms are founded on robust clinical data[81]. The future integration of AI with telemedicine, wearable technology, and personalized healthcare is expected to advance, resulting in more accurate and accessible care. The capacity of AI to forecast, avert, and oversee both mental and cardiovascular health issues simultaneously could markedly enhance the quality of life for individuals with psychocardiological illnesses[81].

7. Future Directions:

Comprehensive strategies for minimizing mental and heart health concerns in cancer patients are increasingly recognized as vital for enhancing their overall well-being and treatment outcomes. Cancer therapies, including chemotherapy, radiation, and immunotherapy, frequently induce considerable physical, emotional, and psychological stress, subsequently affecting cardiovascular health. Consequently, a coordinated and holistic approach that addresses both the mind and body presents a promising future trend in cancer treatment[81].

7.1. Merging Psychological and Cardiac Treatment

Cancer patients frequently encounter various psychological issues, such as anxiety, sadness, and post-traumatic stress, which are associated with an elevated risk of heart disease. Future initiatives should encompass a more integrated approach that amalgamates mental health treatment with cardiovascular services[52]. By establishing collaborative care teams comprising oncologists, cardiologists, psychologists, and social workers, healthcare providers can more efficiently mitigate the mental and cardiac risks linked to cancer. For example, using cognitive behavioral therapy (CBT) or mindfulness-based stress reduction (MBSR) to manage emotional discomfort can alleviate cardiac strain by decreasing cortisol levels associated with heart disease[56].

7.2. Customized Therapeutic Strategies

As cancer therapies become more individualized, there is an escalating demand for personalized holistic care that considers the distinct risk factors confronting each patient. Genomic tests, lifestyle factors, and psychological profiles might collectively enhance a personalized strategy aimed at addressing both mental and cardiovascular health. For a patient at elevated risk of

cardiac issues, the healthcare team may prioritize stress reduction measures, a heart-healthy diet, and the management of treatment-related side effects such as hypertension, while concurrently addressing psychological concerns through therapy. Personalized care may encompass the monitoring of cardiac function through sophisticated imaging modalities or wearable technology that assesses stress and heart rate variability[82].

7.3. Psychophysical Techniques and Rehabilitation

Integrating mind-body techniques like yoga, Tai Chi, and meditation has demonstrated potential in mitigating mental and cardiovascular risks in cancer patients. These techniques not only alleviate anxiety and despair but also enhance cardiovascular health by decreasing blood pressure and mitigating the danger of arrhythmias. Future study will likely investigate the systematic incorporation of these integrative techniques into cancer treatment procedures, particularly regarding recuperation post-surgery or chemotherapy[83].

Physical rehabilitation programs, encompassing exercise routines, are essential for mitigating cardiovascular risks. Cardiac rehabilitation programs integrating aerobic exercise with psychological counseling may serve as a paradigm for cancer patients. Customized physical activities, such as low-impact exercise for those enduring cancer treatments, may enhance circulation, alleviate weariness, and fortify cardiac function. These approaches are most efficacious when synchronized with mental health care to guarantee comprehensive assistance for patients[84].

7.4. Nutritional and Lifestyle Interventions:

Dietary alterations are a crucial aspect of comprehensive cancer treatment. A heart-healthy diet abundant in antioxidants, fiber, and omega-3 fatty acids may mitigate cardiac risks and alleviate cancer treatment side effects such as fatigue and nausea. Recent studies indicate that adopting plant-based diets and supplementing with particular minerals, like vitamin D and magnesium, may contribute to the management of cardiovascular health and mood stabilization. Moreover, promoting smoking cessation, decreasing alcohol intake, and enhancing sleep hygiene can all alleviate hazards to both mental and cardiovascular health[85].

7.5. Digital Health Technologies:

In the future, digital health technology will be crucial in monitoring and alleviating the mental and cardiovascular health concerns encountered by cancer patients. Wearable technologies that monitor heart rate variability, stress levels, and sleep patterns offer real-time input to patients and healthcare practitioners, facilitating early actions upon danger detection. Mobile applications providing cognitive behavioral therapy, mindfulness practices, and physical rehabilitation can enhance compliance with comprehensive treatment regimens. These digital tools provide scalable alternatives to connect with cancer patients without access to in-person holistic care, particularly in rural or underserved regions[86].

CONCLUSIONS:

Incorporating these measures into cancer treatment plans provides the foundation for the development of holistic approaches that will reduce the dangers to patients' mental and cardiovascular health in the future. Treatment that is individualized, patient-centered, and combines psychological and physical therapy is need to be implemented in order to incorporate these tactics. It is conceivable for healthcare systems to be able to provide more effective aid to cancer patients in negotiating the complicated relationship that exists between their mental health, cardiovascular health, and treatment outcomes. This is something that is possible within the context of cancer therapy. This is something that can be accomplished through the employment of technology, mind-body therapies, and collaborative efforts among professionals from a variety of professions. A comprehensive and holistic approach would not only increase the treatment efficacy and long-term survival rates of cancer patients, but it would also improve the quality of life for those who are afflicted with the disease for those who are tormented by it.

REFERENCES:

1. Alwan, A. (2011). *Global status report on noncommunicable diseases 2010*. World Health Organization.
2. Anderson, L., Quinn, T., Glanz, K., Ramirez, G., Kahwati, L., Johnson, D., ... & Task Force on Community Preventive Services. (2009a). *The effectiveness of worksite nutrition and physical activity interventions for controlling employee overweight and obesity*. *American Journal of Preventive Medicine*, 37, 340–357.
3. Barth, J., Critchley, J. A., & Bengel, J. (2008). *Psychosocial interventions for smoking cessation in patients with coronary heart disease*. *The Cochrane Library*.
4. Coley, H. L., Sadasivam, R. S., Williams, J. H., Volkman, J. E., Schoenberger, Y.-M., Kohler, C. L., ... & Ford, D. E. (2013). *Crowdsourced peer-versus expert-written smoking-cessation messages*. *American Journal of Preventive Medicine*, 45, 543–550.

5. Dale, J., Caramlau, I. O., Lindenmeyer, A., & Williams, S. M. (2008). *Peer support telephone calls for improving health*. The Cochrane Library.
6. Ebrahim, S., Taylor, F., Ward, K., Beswick, A., Burke, M., & Davey Smith, G. (2011). *Multiple risk factor interventions for primary prevention of coronary heart disease*. The Cochrane Library, 1.
7. eMarketer Inc. (2013). *Social networking reaches nearly one in four around the world*. Social Media. Available via e Marketer. <http://www.emarketer.com/Article/Social-Networking-Reaches-Nearly-One-Four-Around-World/1009976>. Accessed 19 Feb 2015.
8. Fisher, E. B., Fitzgibbon, M. L., Glasgow, R. E., Haire-Joshu, D., Hayman, L. L., Kaplan, R. M., ... & Ockene, J. K. (2011). *Review and special article: Behavior matters*. *American Journal of Preventive Medicine*, 40, 15–30.
9. Fisher, E. B., Ayala, G. X., Ibarra, L., Cherrington, A. L., Elder, J. P., Tang, T. S., ... & Simmons, D. (2015). *Contributions of peer support to health, health care, and prevention: papers from peers for progress*. *The Annals of Family Medicine*, 13(Suppl. 1), S2–S8.
10. Foster, G., Taylor, S. J., Eldridge, S. E., Ramsay, J., & Griffiths, C. J. (2007). *Self-management education programmes by lay leaders for people with chronic conditions*. *Cochrane Database of Systematic Reviews*, 4(4).
11. Hibbard, M. R., Cantor, J., Charatz, H., Rosenthal, R., Ashman, T., Gundersen, N., ... & Gartner, A. (2002). *Peer support in the community: Initial findings of a mentoring program for individuals with traumatic brain injury and their families*. *The Journal of head trauma rehabilitation*, 17, 112–131.
12. King, K., Meader, N., Wright, K., Graham, H., Power, C., Petticrew, M., ... & Sowden, A. J. (2015). *Characteristics of interventions targeting multiple lifestyle risk behaviours in adult populations: A systematic scoping review*. *PLoS ONE*, 10, 1–13.
13. Lovato, C., Linn, G., Stead, L. F., & Best, A. (2003). *Impact of tobacco advertising and promotion on increasing adolescent smoking behaviours*. *The Cochrane Database of Systematic Reviews*, CD003439.
14. Morrow, A. L., Guerrero, M. L., Shults, J., Calva, J. J., Lutter, C., Bravo, J., ... & Butterfoss, F. D. (1999). *Efficacy of home-based peer counselling to promote exclusive breastfeeding: A randomised controlled trial*. *The Lancet*, 353, 1226–1231.
15. Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., ... & Cifkova, R. (2012). *European guidelines on cardiovascular disease prevention in clinical practice (version 2012)*. *European Heart Journal*, 19, 403–488.
16. *Reducing risk in heart disease: An expert guide to clinical practice for secondary prevention of coronary heart disease*. 2012, Melbourne: National Heart Foundation of Australia.
17. Angermayr, L.D.K., *Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus—a systematic review of randomized controlled trials*. *Annals of Behavioral Medicine*, 2010. **40**.
18. Chou, W.S., et al., *Web 2.0 for health promotion: Reviewing the current evidence*. *American Journal of Public Health*, 2013. **103**.
19. Cotter, A.P., et al., *Internet interventions to support lifestyle modification for diabetes management: A systematic review of the evidence*. *Journal of Diabetes and its Complications*, 2014. **28**.
20. Begum, M., et al., *Mapping the European cancer research landscape: An evidence base for national and Pan-European research and funding*. *European Journal of Cancer*, 2018. **100**.
21. Chen, Y., et al., *Periodontal disease and tooth loss are associated with lung cancer risk*. *BioMed Research International*, 2020.
22. Christensen, A.S.P., et al., *Can a mass media campaign raise awareness of alcohol as a risk factor for cancer and public support for alcohol-related policies?* *Preventive Medicine*, 2019. **126**.

23. Cuschieri, S., E. Pallari, and N. Terzic, *Mapping the burden of diabetes in five small countries in Europe and setting the agenda for health policy and strategic action*. Health Research Policy and Systems, 2021. **19**.
24. Devleesschauwer, B., *European burden of disease network: Strengthening the collaboration*. European Journal of Public Health, 2020. **30**.
25. Donell, L., L. Hoffman-Goetz, and J.N. Clarke, *Portrayal of genetic risk for breast cancer in ethnic and non-ethnic newspapers*. Women & Health, 2004. **40**.
26. Flor, L.S., M.B. Reitsma, and V. Gupta, *The effects of tobacco control policies on global smoking prevalence*. Nature Medicine, 2021.
27. Huffman, M.D., A. Baldrige, and G.S. Bloomfield, *Global cardiovascular research output, citations, and collaborations: A bibliometric analysis*. PLoS ONE, 2013. **8**.
28. Hurry, M., et al., *Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops*. International Journal of Technology Assessment in Health Care, 2020. **36**.
29. Ivanov, V.K., V.V. Kashcheev, and S.Y. Chekin, *Radiation-epidemiological studies of thyroid cancer incidence in Russia after the Chernobyl accident (estimation of radiation risks, 1991–2008 follow-up period)*. Radiation Protection Dosimetry, 2012. **151**.
30. Kawasaki, M., Y. Ikeda, and E. Ikeda, *Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer*. Cancer, 2020.
31. Kowall, B. and A. Stand, *Mistakes and drawbacks in german newspaper articles on epidemiologic studies: "Meat consumption and colorectal cancer" as an example*. Gesundheitswesen, 2019. **81**.
32. Klingelhofer, D., M. Braun, and N. Schoffel, *Gastric cancer: Bibliometric analysis of epidemiological, geographical and socio-economic parameters of the global research landscape*. International Journal of Health Policy and Management, 2021. **10**.
33. Lewison, G., *The definition and calibration of biomedical subfields*. Scientometrics, 1999. **46**.
34. Li, A. and G. Lewison, *Chinese cancer research in 2009–18 and the disease burden*. Cancer Management and Research, 2020. **12**.
35. Lin, M.Q., C.L. Lian, and P. Zhou, *Analysis of the trends in publications on clinical cancer research in mainland China from the surveillance, epidemiology, and end results (SEER) database: Bibliometric study*. JMIR Medical Informatics, 2020. **8**.
36. Lundkvist, A., Z. El-Khatib, and N. Kalra, *Policy-makers' views on translating burden of disease estimates in health policies: Bridging the gap through data visualization*. Archives of Public Health, 2021. **79**.
37. Albagoush, S.A. and F. Limaiem, *HER2*. StatPearls. 2022, Treasure Island: StatPearls Publishing LLC.
38. Alves, C.R., et al., *Aerobic exercise training as therapy for cardiac and cancer cachexia*. Life Sci, 2015. **125**.
39. Andres, M.S., J. Pan, and A.R. Lyon, *What does a cardio-oncology service offer to the oncologist and the haematologist?* Clin Oncol (R Coll Radiol), 2021. **33**.
40. Antunes, J.M.M., R.M.P. Ferreira, and D. Moreira-Gonçalves, *Exercise training as therapy for cancer-induced cardiac cachexia*. Trends Mol Med, 2018. **24**.
41. Asteggiano, R., et al., *Cardiology care delivered to cancer patients*. Eur Heart J, 2020. **41**.
42. Boer, R.A., et al., *Cancer and heart disease: associations and relations*. Eur J Heart Fail, 2019. **21**.
43. Bowles, E.J., et al., *Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study*. J Natl Cancer Inst, 2012. **104**.
44. Cardinale, D., et al., *Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy*. Circulation, 2015. **131**.

45. Cardinale, D., et al., *Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy*. J Am Coll Cardiol, 2010. **55**.
46. Cavalheri, V., et al., *Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer*. Cochrane Database Syst Rev, 2019. **6**.
47. Chen, Y., et al., *Traditional cardiovascular risk factors and individual prediction of cardiovascular events in childhood cancer survivors*. J Natl Cancer Inst, 2020. **112**.
48. Chung, W.P., et al., *Real-time exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: a randomized controlled trial*. Ann Phys Rehabil Med, 2022. **65**.
49. Cuomo, A., et al., *Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients*. ESC Heart Fail, 2022. **9**.
50. Curigliano, G., et al., *Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations*. Ann Oncol, 2020. **31**.
51. Daugaard, G., et al., *Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction*. Eur J Heart Fail, 2005. **7**.
52. Dobson, R., *BSE and BCOS guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab*. J Am Coll Cardiol CardioOnc, 2021. **3**.
53. Domercant, J., N. Polin, and E. Jahangir, *Cardio-oncology: a focused review of anthracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management*. Ochsner J, 2016. **16**.
54. Foulkes, S.J., et al., *Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the Breast Cancer Randomized Exercise Intervention (BREXIT) study*. Circulation, 2022.
55. Geisberg, C.A. and D.B. Sawyer, *Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage*. Curr Hypertens Rep, 2010. **12**.
56. Geršak, B.M., et al., *Relationship between quality of life indicators and cardiac status indicators in chemotherapy patients*. Zdr Varst, 2021. **60**.
57. Herrmann, J., et al., *Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement*. Eur Heart J, 2022. **43**.
58. Howden, E.J., et al., *Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients*. Eur J Prev Cardiol, 2019. **26**.
59. Jordan, J.H., et al., *Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors*. Circ Cardiovasc Imaging, 2016.
60. Kerrigan, D.J., et al., *Cardiac rehabilitation improves fitness in patients with subclinical markers of cardiotoxicity while receiving chemotherapy: a randomized controlled study*. J Cardiopulm Rehabil Prev, 2022.
61. Kitayama, H., et al., *High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients*. Breast Cancer, 2017. **24**.
62. Koop, Y., et al., *Oncology professionals' perspectives towards cardiac surveillance in breast cancer patients with high cardiotoxicity risk: a qualitative study*. PLoS ONE, 2021. **16**.
63. Koop, Y., et al., *Quality of life in breast cancer patients with cancer treatment-related cardiac dysfunction: a qualitative study*. Eur J Cardiovasc Nurs, 2022. **21**.
64. Kubota, Y., et al., *Physical activity and lifetime risk of cardiovascular disease and cancer*. Med Sci Sports Exerc, 2017. **49**.
65. Lee, K., et al., *Feasibility of high intensity interval training in patients with breast cancer undergoing anthracycline chemotherapy: a randomized pilot trial*. BMC Cancer, 2019. **19**.

66. Leerink, J.M., et al., *Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review*. Heart, 2019. **105**.
67. López-Sendón, J., et al., *Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry*. Eur Heart J, 2020. **41**.
68. Lyon, A.R., et al., *Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society*. Eur J Heart Fail, 2020. **22**.
69. McDonagh, T.A., et al., *2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure*. Eur Heart J, 2021. **42**.
70. Melendez, G., *Cardiotoxicity of anthracyclines*. Front Cardiovasc Med, 2020. **7**.
71. Michel, L., et al., *Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis*. Eur J Heart Fail, 2020. **22**.
72. Minami, M., S. Matsumoto, and H. Horiuchi, *Cardiovascular side-effects of modern cancer therapy*. Circ J, 2010. **74**.
73. Ness, S., *VAT/GST harmonisation challenges for digital assets such as bitcoin and NFTs in the EU following Case C-264/14 (Skatteverket v David Hedqvist)*. International Cybersecurity Law Review, 2024. **5**(3): p. 459-490.
74. Agarwal, M., et al., *Tyrosine kinase inhibitor-induced hypertension*. Curr Oncol Rep., 2018. **20**.
75. Aichberger, K.J., S. Herndlhofer, and G.H. Schernthaner, *Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML*. Am J Hematol., 2011. **86**.
76. Amsterdam, E.A., N.K. Wenger, and R.G. Brindis, *2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines*. J Am Coll Cardiol., 2014. **64**.
77. Bharadwaj, A., J. Potts, and M.O. Mohamed, *Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA*. Eur Heart J., 2020. **41**.
78. Budolfson, C., J. Faber, and D. Grimm, *Tyrosine kinase inhibitor-induced hypertension: role of hypertension as a biomarker in cancer treatment*. Curr Vasc Pharmacol., 2019. **17**.
79. Cameron, A.C., R.M. Touyz, and N.N. Lang, *Vascular complications of cancer chemotherapy*. Can J Cardiol., 2016. **32**.
80. Cardinale, D., M. Salvatici, and M.T. Sandri, *Role of biomarkers in cardioncology*. Clin Chem Lab Med., 2011. **49**.
81. Díaz-Gavela, A.A., et al., *Breast radiotherapy-related cardiotoxicity. When, how, why. Risk prevention and control strategies*. Cancers (Basel), 2021. **13**.
82. Yang, H.L., et al., *Early moderate intensity aerobic exercise intervention prevents doxorubicin-caused cardiac dysfunction through inhibition of cardiac fibrosis and inflammation*. Cancers (Basel), 2020. **12**.
83. Williamson, T., et al., *Cancer and cardiovascular disease: the impact of cardiac rehabilitation and cardiorespiratory fitness on survival*. Int J Cardiol, 2021. **343**.
84. White, J., et al., *Early access to a cardio-oncology clinic in an Australian context: a qualitative exploration of patient experiences*. Cardiooncology, 2022. **8**.
85. Westphal, J.G. and P.C. Schulze, *Exercise training in cancer related cardiomyopathy*. J Thorac Dis, 2018. **10**.
86. Tonry, C., et al., *Circulating biomarkers for management of cancer therapeutics related cardiac dysfunction*. Cardiovasc Res, 2022.

UNDER PEER REVIEW